Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model.
This study examined the consequences of systemic treatment with either L-dopa or MK-801 on the levels of mRNAs encoding the 65 and 67 kDa isoforms of glutamate decarboxylase (GAD65 and GAD67) in the striatum and globus pallidus (GP) of rats rendered hemiparkinsonian by intranigral 6-hydroxydopamine injection. GADs mRNA levels were assessed by means of in situ hybridization histochemistry. In the striatum, dopamine denervation resulted in increased GAD67 mRNA levels at the rostral and caudal levels, whereas GAD65 showed selective increase at the caudal level. L-dopa and MK-801 treatments showed differential effects on the two GAD isoform levels in rats with 6-hydroxydopamine lesion. The lesion-induced increases in GAD67 transcripts were potentiated by L-dopa but unaffected by MK-801, whereas the increases in GAD65 were suppressed by MK-801 but unaffected by L-dopa. These data suggest a heterogeneity of glutamate-dopamine interaction in the anteroposterior extent of the striatum and show that NMDA-mediated mechanisms are involved in the 6-hydroxydopamine lesion-induced transcriptional changes in striatal GAD65 but not GAD67. In GP, the 6-OHDA lesion elicited increases in both GAD65 and GAD67 mRNA levels. L-dopa or MK-801 treatment suppressed the lesion-induced augmentations in the two GADs mRNA levels. These results indicate that dopamine denervation-induced changes in the functional activity of GP neurons involve both dopamine and glutamate NMDA receptor-mediated mechanisms. Comparison between the effects of L-dopa and MK-801 treatments on markers of the activity of striatal and pallidal GABA neurons further suggest that the impact of these treatments at the GP level do not depend solely on the striatopallidal input.
Bacci
Jean-Jacques
JJ
Laboratoire de Neurobiologie Cellulaire et Fonctionnelle, UPR 9013, CNRS, 13 402 Marseille Cedex 20, France.
Salin
Pascal
P
Kerkerian-Le Goff
Lydia
L
D000818:Animals; D016291:Dizocilpine Maleate / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005917:Globus Pallidus / Q000187:drug effects* / Q000201:enzymology; D005968:Glutamate Decarboxylase / Q000096:biosynthesis*; D007279:Injections, Subcutaneous; D007527:Isoenzymes / Q000096:biosynthesis*; D007980:Levodopa / Q000494:pharmacology* / Q000627:therapeutic use; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar
D007527:Isoenzymes; D012333:RNA, Messenger; D007980:Levodopa; D016291:Dizocilpine Maleate; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; C401141:glutamate decarboxylase 2